A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT02451943 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

509

Enrollment

INDUSTRY

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab
DRUG: Doxorubicin
DRUG: Placebo

Sponsor

Eli Lilly and Company